A149Objectives: To understand why dronedarone failed to unseat amiodarone as the primary antiarrhythmic treatment of choice for persistent AF, thus uncovering the clinical outcome requirements for a future AF therapy to achieve optimal market access. MethOds: Review published HTA reports and clinical trial outcomes for dronedarone to assess market access outcomes and associated Payer rationale for decision-making. Interview ten (10) managed care medical directors and AF key opinion leaders (KOLs) in US and thirteen (13) ex-Payers and AF KOLs in Europe (mix of stakeholders encompassing France, Germany, Italy, Spain, and UK) for validation and gap filling. Results: Driven by benefits in all efficacy outcomes other than cardiovascular-related hospitalizations, Payers perceive amiodarone as more efficacious than dronedarone. The significant number of deaths during the highrisk PALLAS study crippled the safety image of dronedarone. Finally, a prohibitive price at launch contributed to a multiplicity of negative HTA assessments. In order to succeed where dronedarone failed and qualify as a step function increase over the standard-of-care amiodarone, Payers require at least: 40% reduction in AF recurrence; 30% relative risk reduction in hospitalizations compared to amiodarone; and fewer than 1% deaths as part of the clinical evidence package. Lower rates of bradyarrhythmia, liver toxicity, and no proarrhythmia will drive a favorable regulatory safety evaluation compared to amiodarone. cOnclusiOns: The sub-optimal market access and relatively low utilization of dronedarone resulted primarily from a failure to demonstrate an improvement in recurrence as compared to amiodarone, as well as a significant number of deaths during pivotal trials. Manufacturers considering development of novel antiarrhythmics should strive for equivalent efficacy but superior safety to amiodarone if a 40% reduction in recurrence is not clinically feasible.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.